Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.

<h4>Background</h4>This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset.<h4>Methods</h4>We obtained the data f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shiu-Dong Chung, Shih-Ping Liu, Herng-Ching Lin, Li-Hsuan Wang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ad29902629e042ffbb5493692f2a709c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad29902629e042ffbb5493692f2a709c
record_format	dspace
spelling	oai:doaj.org-article:ad29902629e042ffbb5493692f2a709c2021-11-11T08:21:06ZIncreased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.1932-620310.1371/journal.pone.0101254https://doaj.org/article/ad29902629e042ffbb5493692f2a709c2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24971988/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset.<h4>Methods</h4>We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period.<h4>Results</h4>Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95% confidence interval (CI): 1.89∼9.64) per 100 person-years and 2.14 (95% CI: 1.31∼3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p<0.002). After adjusting for age, monthly income, and the Charlson Comorbidities Index score, PC patients who received treatment with GnRH agonists were more likely to have been hospitalized for pneumonia during the 1-year follow-up period than PC patients who did not receive treatment with GnRH agonists (hazard ratio: 1.92, 95% CI: 1.10∼3.36).<h4>Conclusions</h4>PC patients who received treatment with GnRH agonists had an increased risk of pneumonia.Shiu-Dong ChungShih-Ping LiuHerng-Ching LinLi-Hsuan WangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 6, p e101254 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shiu-Dong Chung Shih-Ping Liu Herng-Ching Lin Li-Hsuan Wang Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
description	<h4>Background</h4>This study aimed to investigate the relationship between the use of gonadotropin-releasing hormone (GnRH) agonists and subsequent risk of pneumonia in patients with prostate cancer (PC) using a population-based dataset.<h4>Methods</h4>We obtained the data from Taiwan's Longitudinal Health Insurance Database 2000. We included 2064 PC in this study. Of the sampled PC patients, 1207 received treatment with GnRH agonists. We individually traced each PC patient for a 1-year period to identify those who were hospitalized with pneumonia. We performed a Cox proportional hazard regression to explore the association between the use of GnRH agonists and the risk of pneumonia during the 1-year follow-up period.<h4>Results</h4>Incidence rates of pneumonia during the 1-year follow-up period were 4.35 (95% confidence interval (CI): 1.89∼9.64) per 100 person-years and 2.14 (95% CI: 1.31∼3.32) per 100 person-years for PC patients who did and those who did not receive treatment with GnRH agonists, respectively. The log-rank test suggested that there was a significant difference in the 1-year pneumonia-free survival rate between PC patients who did and those who did not receive treatment with GnRH agonists (p<0.002). After adjusting for age, monthly income, and the Charlson Comorbidities Index score, PC patients who received treatment with GnRH agonists were more likely to have been hospitalized for pneumonia during the 1-year follow-up period than PC patients who did not receive treatment with GnRH agonists (hazard ratio: 1.92, 95% CI: 1.10∼3.36).<h4>Conclusions</h4>PC patients who received treatment with GnRH agonists had an increased risk of pneumonia.
format	article
author	Shiu-Dong Chung Shih-Ping Liu Herng-Ching Lin Li-Hsuan Wang
author_facet	Shiu-Dong Chung Shih-Ping Liu Herng-Ching Lin Li-Hsuan Wang
author_sort	Shiu-Dong Chung
title	Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
title_short	Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
title_full	Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
title_fullStr	Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
title_full_unstemmed	Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
title_sort	increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/ad29902629e042ffbb5493692f2a709c
work_keys_str_mv	AT shiudongchung increasedriskofpneumoniainpatientsreceivinggonadotropinreleasinghormoneagonistsforprostatecancer AT shihpingliu increasedriskofpneumoniainpatientsreceivinggonadotropinreleasinghormoneagonistsforprostatecancer AT herngchinglin increasedriskofpneumoniainpatientsreceivinggonadotropinreleasinghormoneagonistsforprostatecancer AT lihsuanwang increasedriskofpneumoniainpatientsreceivinggonadotropinreleasinghormoneagonistsforprostatecancer
_version_	1718439340467552256

Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.

Ejemplares similares